Primary Care

JAK Inhibitors

Questions discussed in this category

Do patient co-morbidities impact when you prescribe oral jak inhibitors?

Are you less likely to prescribe it for patients with dyslipidemia or autoimmune disease?

3 Answers available

What is your approach to management of hyperlipidemia in patients taking JAK inhibitors?

1 Answer available

How do you approach monitoring when using combination JAK inhibitors and methotrexate in RA?

1 Answer available

Do you have concerns with the use of oral contraceptives in patients on JAK inhibitors given the black box warning for thromboembolic events?

How has this impacted your counseling and management?

2 Answers available

Do you ever consider using a higher dose of upadacitinib (30 mg daily) for rheumatoid arthritis in patients who fail to respond/partially respond to established dosing of 15 mg daily?

1 Answer available

Should JAK inhibitors and anti-IL6 medications be avoided in patients with known diverticulosis?

2 Answers available

Papers discussed in this category

Arthritis & rheumatology (Hoboken, N.J.), 2016-11

Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments.

Annals of the rheumatic diseases, 2019-04

Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study.

Annals of the rheumatic diseases, 2023 May 29

JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications.

Arthritis & rheumatology (Hoboken, N.J.), 2017-03

Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment.

Annals of the rheumatic diseases, 2019 Jul 30

Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response.

N Engl J Med,

Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.

Autoimmunity reviews, 2023 Dec 20

Implementation of regulatory guidance for JAK inhibitors use in patients with immune-mediated inflammatory diseases: An international appropriateness study.

Related Topics in Primary Care